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Abstract
Elevated tumor interstitial fluid pressure (TIFP) is a characteristic of most solid tumors. Clinically, TIFP may hamper
the uptake of chemotherapeutic drugs into the tumor tissue reducing their therapeutic efficacy. In this study, a
means of modulating TIFP to increase the flux of macromolecules into tumor tissue is presented, which is based
on the rationale that elevated plasma colloid osmotic pressure (COP) pulls water from tumor interstitium lowering
the TIFP. Concentrated human serum albumin (20% HSA), used as an agent to enhance COP, reduced the TIFP
time-dependently from 8 to 2 mm Hg in human tumor xenograft models bearing A431 epidermoid vulva carcinomas.
To evaluate whether this reduction facilitates the uptake of macromolecules, the intratumoral distribution of fluo-
rescently conjugated dextrans (2.5 mg/ml) and cetuximab (2.0 mg/ml) was probed using novel time domain near-
infrared fluorescence imaging. This method permitted discrimination and semiquantification of tumor-accumulated
conjugate from background and unspecific probe fluorescence. The coadministration of 20% HSA together with
either dextrans or cetuximab was found to lower the TIFP significantly and increase the concentration of the sub-
stances within the tumor tissue in comparison to control tumors. Furthermore, combined administration of 20% HSA
plus cetuximab reduced the tumor growth significantly in comparison to standard cetuximab treatment. These data
demonstrate that increased COP lowers the TIFP within hours and increases the uptake of therapeutic macromole-
cules into the tumor interstitium leading to reduced tumor growth. This model represents a novel approach to facil-
itate the delivery of therapeutics into tumor tissue, particularly monoclonal antibodies.
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Introduction
Great efforts have been made to increase the specificity of targeted
therapeutics in the fight against cancer; there are, however, barriers
that limit uptake in the desired tumor site [1]. The central protago-
nist that counteracts the enrichment of pharmacological compounds
within solid tumors is their enhanced tumor interstitial fluid pres-
sure (TIFP).
Originally, in 1950, Young et al. [2] hypothesized that hydrostatic
pressures in tumor interstitium were elevated. However, it was approx-
imately 30 years before others and we demonstrated that the interstitial
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fluid pressures (IFP) in tumors were indeed increased [3,4]. Later,
it has been shown that a high TIFP is a general property of solid
tumors in experimental animals and humans [5]. Following these
observations, it has been suggested that this increase in TIFP acts
as a barrier against the efficient transvascular transport of therapeutics
into tumors [6,7]. In normal tissue, the IFP has a value of −2 to
0 mm Hg, which is in stark contrast to the IFP in solid human or
experimental tumors that can reach values between 3 and 40 mm Hg
[8]. The origin of TIFP is mainly attributed to lymph-vessel abnor-
malities, abnormal vasculature, and the highly permeable blood vessel
network in the tumor area [9–11]. In addition to these trigger fac-
tors, it is also assumed that increased contractility of fibroblasts in
the tumor surrounding stroma plays a pivotal role in the develop-
ment of high TIFP values [5]. Small molecules are much less affected
by an enhanced TIFP, being primarily distributed through diffusional
transport. However, macromolecules, such as monoclonal antibodies,
accumulate through convectional transcapillary transport, which is
counteracted by TIFP [1,5,11,12]. Thus, elevated TIFP is suggested
to hamper the transfer of macromolecules such as monoclonal anti-
bodies from the vascular system into the tumor interstitium surround-
ing the tumor cells [7,9]. Besides implications for tumor therapy, TIFP
is also known to cause mechanical stress on the tumor capsule, a well-
known trigger factor for cell proliferation [13,14].
In capillaries, Starling Forces, that is, the hydrostatic and colloid
osmotic pressures (COPs) in capillaries and interstitium, regulate
the net transcapillary filtration pressure [15]. In normal human cap-
illaries, a high COP in the plasma tends to keep fluid in the vessels,
whereas a high hydrostatic pressure in the capillaries together with a
low COP and negative (or close to zero) IFP within the interstitium
acts oppositely and results in fluid filtration into the interstitium,
supporting tissue nutrition. In tumors, a high TIFP may counteract
filtration and thus, delivery of therapeutic agents [5,16].
In the current work, in a xenograft tumor model, we tested the
hypothesis whether an increase of the vascular COP by systemically
administered human serum albumin (HSA) generates a fluid efflux
from tumor tissue resulting in a decreased TIFP. Consecutively, the
uptake of intravenously (IV) applied fluorescent-labeled macromo-
lecular compounds (dextran or cetuximab) into the tumor tissue was
measured. Data were obtained by fluorescence microscopy and novel-
infrared, time domain optical imaging. Particularly, the latter allows
semiquantification of the intratumoral substance accumulation. By
using these methods, it was found that systemic application of concen-
trated HSA increases the uptake of macromolecules into solid tumors
and delays tumor growth. This novel approach offers new perspectives
for the application of macromolecular anticancer therapeutics.
Materials and Methods
Drugs and Cells
The A431 epidermoid vulva carcinoma cell line was purchased from
the American Type Culture Collection (ATCC/LCSC Standards,
Wesel, Germany) and was cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen, Karlsruhe, Germany) containing 10% fetal calf
serum. Phosphorylation of p44/42 was detected using a phosphospecific
antibody (Thr202/Tyr204; Cell Signaling Technology, Frankfurt/Main,
Germany). Detection of total p44/42 (Cell Signaling Technology)
served as a loading control.
TRITC-, Alexa488-, or Alexa680-labeled dextrans (40 kDa; Invitrogen)
or Alexa680-labeled cetuximab (2 mg/ml; a kind gift from Dr. S. Kappel,
Department of Gynaecology and Obstetrics, Frankfurt/Main, Germany,
and Dr. Steinbach, Merck, Darmstadt, Germany) monoclonal anti-
body (mAb) was used to study the uptake of macromolecules into
tumors. Cetuximab was conjugated using SAIVI Alexa Fluor 680 La-
beling Kit (Invitrogen). In the animal experiments, concentrated HSA
(20% HSA; Octapharma, Lachen, Switzerland or Baxter, Vienna,
Austria) was used to increase the plasma COP.
Tumor Models
In the experiments, female NMRI (Naval Medical Research In-
stitute) mice (5-6 weeks, 18-22 g; Harlan Winkelmann, Borchen,
Germany) and female non-obese diabetic/severe combined immuno-
deficient (NOD/SCID) mice (5-6 weeks; 18-22 g; Gades Animal
Facility, University of Bergen, Bergen, Norway, and Møllegard,
Skensved, Danmark) were subcutaneously (SC) injected on both flanks
with 5 × 106 A431 cells. In other experiments, female Rowett nude
rats (180-200 g; Gades Animal Facility, University of Bergen and
Harlan Winkelmann) were SC injected in the neck with 1 × 107
A431 cells. All animal experiments were approved in accordance with
the German animal welfare regulations and the guidelines of the
Norwegian State Commission for Laboratory Animals. The animals
were kept under specific pathogen-free conditions. Sterilized food
and tap water were given ad libitum. Mice were anesthetized using
ketamine/xylazine (100/10 mg/kg, intraperitoneally; Pharmacia,
Erlangen, and BayerVital, Leverkusen, Germany) and rats using
pentobarbital (60 mg/kg, intraperitoneally; Sigma, Taufkirchen, Ger-
many). All animals were placed on regulated heating pads to keep the
body temperature at 37 to 37.5°C during the experiments. After tu-
mor excision, anesthetized animals were killed.
During the experiments, Rowett rats received an IV infusion of 5 ml
of 20% HSA, having a COP of 80 mm Hg for 1 hour (84 μl/min)
using a clinical perfusor (Braun, Melsungen, Germany). At distinct
time points of the infusion, animals received an IV injection of fluo-
rescent dextrans. In contrast, NOD/SCID mice bearing bilateral
A431 tumors (>300 mm3) received an IV bolus injection of 500 μl
of 20% HSA, 4% HSA (COP, 16 mm Hg), or 0.9% NaCl. Thirty
minutes later, the animals were IV injected with 50 μl of Alexa680-
coupled dextrans (2.5 mg/ml) or Alexa680-labeled cetuximab (2 mg/ml).
Tumor Interstitial Fluid Pressure Measurements
Tumor interstitial fluid pressure was evaluated as reported pre-
viously using the “micropuncture” technique [17]. Tumor interstitial
fluid pressure measurements were done every 3 days using sharpened
glass capillaries (tip size, 4-10 μm; outer diameter, 1.0 mm; inner
diameter, 0.58 mm) inserted in the outermost tumor tissue layers.
The glass capillaries were connected to a servocontrolled counter-
pressure system. The pressure was recorded using a pressure transducer
(1280 C; Hewlett Packard, Waltham, MA) connected to an amplifier
and recorder (Gould Instruments, Ballainvilliers, France). Glass capil-
laries were filled with 0.5 M NaCl solution colored with Evans Blue
dye (Merck) to visualize the capillary tip. Recording of TIFP started
when tumors reached a volume of 500 mm3 or greater. The measure-
ments were performed 0.4 to 0.6 mm inside the tumor tissue using a
micromanipulator (Leitz, Wetzlar, Germany) and a stereomicroscope
(Wild M5; Leitz) for visual guidance of the glass capillaries. Special
care was taken to avoid compression or stretching of tumor tissue
during the capillary insertion. Measurements were accepted when
the following three criteria were met: 1) an increased feedback gain
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did not change the recorded pressure values; 2) suction applied by the
servocontrolled pump gave an increased electric resistance in the
capillary, verifying an open communication to interstitial fluid pressure
because of lower tonicity of the fluid entering the capillary; 3) after the
measurement, the zero value in a saline-filled cup placed at the level of
micropipette insertion was unchanged compared with the premeasure-
ment value.
Colloid Osmotic Pressure Measurements
Colloid osmotic pressure was analyzed in serum samples using a mi-
crocolloid osmometer with membranes with a cutoff size of 30 kDa
[18]. A minimum of 0.5 μl of serum was needed to perform the mea-
surement. Usually, samples of 1 to 1.5 μl were applied to the osmom-
eter membrane. All samples were collected at distinct time points
before, during, or after the infusion of animals with 20% HSA (Baxter,
Unterschleisheim, Germany) or control solutions. Before the start of a
new test run, the osmometer was calibrated using PBS solution.
Immunofluorescence
For immunofluorescence studies, tumors were embedded inTissueTek-
Medium (Jung, Heidelberg, Germany) and immediately frozen. Frozen
samples were cut in thin slides of 8 to 12 μm using a Leica Kryostat
(Leica Microsystems, Wetzlar, Germany), placed on object slides, and
stored at 4°C in nontransparent boxes to protect fluorescent dyes from
bleaching. Sections were examined using anOlympus BX5 fluorescence
microscope (Olympus, Hamburg, Germany).
Time Domain Optical Imaging
Time domain optical imaging experiments were performed with an
Optix MX2 system (ART, Inc, Saint Laurent, Quebec, Canada) in
near-infrared (NIR) configuration. This consisted of a 670-nm pulsed
laser diode with a repetition rate of 80 MHz (translating to an acqui-
sition time window of 12.5 nanoseconds) using a PMT detector with a
700-nm long-pass filter. A translational stage and galvanometric mir-
rors enable raster scanning along x and y directions, with scanning res-
olutions of 1 mm used. Briefly, mice were depilated at the region of
interest, and background images were acquired under isoflurane anes-
thesia (1.5% isoflurane) at distinct time points (10-360 minutes) after
administration of Alexa680-labeled dextran or cetuximab. Mice were
placed on an adjustable stage in the imaging system, where a two-
dimensional scanning region and white light image encompassing
the area of the mouse were acquired through a top-reviewing digital
camera. The samples were then automatically moved into the imaging
chamber for scanning. The laser power for each mouse and time point
was optimized per sample before scanning. Resultant images were an-
alyzed with Optix Optiview (2.0.01 and 2.01.00) software (ART, Inc).
Conventional whole-body reflectance fluorescence imaging and
fluorescence imaging using an epi-illumination or trans-illumination
source rely on a high signal-to-background ratio to determine fluo-
rescence accumulation in a target organ. However, quantification or
semiquantification of the desired fluorescent signal is frustrated by
inability to decouple background fluorescence, animal autofluores-
cence, and accumulated fluorescence, particularly when using exog-
enous fluorescent probes. In time domain imaging (Figure 1A), using
a pulsed laser diode, raster scan (in this instance, 1-mm resolution =
fluorescence images of pixel size 1 mm2), and time-correlated detec-
tion system, measurement of the fluorescence signal and its decay
curve over time per fluorescence image pixel (or raster point) is per-
mitted [19]. Thus, this information can be used to generate the fluo-
rescence decay profile, or fluorescence lifetime, per pixel. Before
injection of the contrast reagent, a background scan of the region
of interest, including tumor and normal tissues, is generated (Fig-
ure 1B). Each pixel of the resultant image corresponds to the fluores-
cence intensity per predetermined raster point and its subsequent
fluorescence lifetime. Thus, by cumulating all pixels in the back-
ground image, one can determine the distribution of all fluorescence
lifetimes and their intensities (generally, autofluorescence) per ani-
mal. After administration of NIR imaging probe (Figure 1C , dem-
onstrated here for mAb labeled with Alexa680) and subsequent
imaging, analysis of the fluorescence image reveals differences in
the fluorescence lifetime of normal and tumor tissue pixels. Accord-
ingly, distinct lifetime distributions can be observed for autofluo-
rescence, background fluorescence in normal tissues (consequent
of circulating contrast reagent), and tumor-associated fluorescence
[20,21]. It has previously been demonstrated that time domain im-
aging can be used to decouple the specific lifetimes of fluorescent
proteins from that of tissue autofluorescence with similar spectral
properties [19] and that fluorescence lifetimes of imaging probes are
affected by environmental changes such as pH and [Ca2+] [22,23].
By gating for both the fluorescence lifetime and fluorescence intensity
range of the specific lifetime distribution of tumor-associated fluores-
cence, one can exclude autofluorescence and background fluorescence
(Figure 1D). Ultimately, this method permits the approximation of
tumor-associated fluorescence.
Results
Acute Reduction in TIFP Results with Increased Uptake
of Dextrans
Initially, we recorded the increase of TIFP during tumor growth.
Using the A431 tumor xenograft model (NMRI mice and rnu/rnu
rats), we found that TIFP increased uniformly as a function of tumor
volume (Figure 2A) when measured using the “wick-in-needle” tech-
nique at distinct time points (n = 10 tumors per species). Conse-
quently, we evaluated if lowering of TIFP facilitated the uptake of
Figure 1. Time domain molecular imaging. (A) Using a 670-nm pulsed laser diode, (1) the subject is irradiated with NIR light resulting in
(2) excitation of fluorophore and (3) subsequent detection of fluorescence emission. Each pixel of the resultant image encodes not only
the fluorescence intensity but also its fluorescence lifetime. (B) Before injection of fluorescent contrast reagent, background scans are
completed, and analysis of fluorescence lifetimes on a per-pixel basis permits determination of the distribution of the animal’s endog-
enous autofluorescence lifetimes. (C) Subsequent injection of contrast reagent (in this instance, fluorescently labeled antibody), imag-
ing, and analysis of fluorescence lifetime distribution reveal two new peaks corresponding to tumor-associated fluorescence and normal
tissue-accumulated background fluorescence lifetimes. (D) By gating (fluorescence intensity and lifetime range) for the specific lifetime
distribution of interest, an image of tumor-associated fluorescence can be generated to quantify tumoral fluorescence only.
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macromolecules. Thus, the uptake of IV injected fluorescently la-
beled dextrans in the tumor interstitial space was determined after
lowering of TIFP by tumor puncture, as previously described [14].
As illustrated in Figure 2B (panels 1 and 2), uptake of dextrans in
punctured tumors was significantly enhanced in comparison to un-
treated control tumors. In other tissues (Figure 2B, panels 3 and 4 ),
for example, kidney, capsule puncture had no effect on the uptake of
labeled dextrans. Although these experiments clearly demonstrated
that tumor puncture lowers TIFP and enhances the uptake of macro-
molecules, such methodology is clinically impracticable.
Increased COP in Plasma Increases Tumor Uptake of Dextrans
Thus, we tested if an increase of the vascular COP by systemically
administered HSA would generate a fluid efflux from tumor tissue
resulting in a decreased TIFP. Consequently, IV administration of
20% HSA (wt/vol) raised the plasma COP significantly resulting
in a TIFP decrease (Figure 3A). To examine if this approach was
sufficient to significantly increase intratumoral uptake of macromo-
lecules, A431 tumor-bearing rats were infused with 20% HSA fol-
lowed by IV injection of fluorescently labeled dextrans at distinct
time points. It was found that the uptake of dextrans into the tumor
interstitium was increased in rats injected between 2 and 3 hours
after the HSA application (Figure 3B, panels 3 and 4 ) compared with
untreated control tumors (Figure 3B, panel 1) and in rats injected
only 30 minutes after the HSA application (Figure 3B, panel 2).
Increased Tumor Uptake of Macromolecules Can Be Visualized
by Time Domain Fluorescence Imaging
To semiquantify this uptake in vivo, we used a novel time domain
fluorescence imaging modality to specifically quantify fluorescence
Figure 2. Tumor interstitial fluid pressure measurements and the effect of tumor puncture on the uptake of dextrans. (A) Comparison of
TIFP values of A431 tumors in NMRI mice and Rowett nude rats. In both animal species, TIFP increased with tumor volume. Data are
shown as mean (±SEM) increase of TIFP. n = 10 per species. (B) Uptake of TRITC-labeled dextrans in TIFP-lowered A431 tumors and
kidney tissue of NMRI mice. A431 tumors were punctured using 20-G needles. Afterwards, mice were injected IV with 50 μl of fluores-
cent dextran solutions (2.5 mg/ml). All tissue samples, namely, (1) untreated control tumor, (2) punctured tumor, (3) untreated kidney
tissue, and (4) punctured kidney tissue, were excised 30 minutes after the application of the fluorescent dextrans.
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the accumulated fluorescent dextran in A431 tumors. NOD/SCID
mice bearing SC A431 tumors were pretreated with 0.9% NaCl so-
lution as volume control, low-concentration HSA (4%) control, or
20% HSA, 30 minutes before injection of dextran labeled with
Alexa680 and imaged for 6 hours. Resultant images (Figure 4A) were
gated for fluorescence lifetimes of accumulated tumoral fluorescence
(Figure 4B) from circulating fluorescence or exogenous autofluo-
rescence, facilitating distinction of tumoral-only accumulated fluo-
rescence (Figure 4A, third picture). Subsequently, no difference in
tumoral accumulated fluorescence was observed between the NaCl
and 4% HSA groups. In contrast, the injection of 20% HSA facili-
tated a significant uptake and delayed intratumoral dextran clearance
(Figure 4C ), demonstrating that enhanced uptake of macromole-
cules is HSA concentration–dependent. Of note, the intratumoral
uptake of dextrans was increased approximately 95% in mice that
were treated with 20% HSA for 30 minutes (Figure 4D). Interspecies
differences were observed in dextran uptake kinetics between mice
and rats; however, in both species, the injection of 20% HSA led
to considerably increased uptake of macromolecules.
Infusion of Hyperoncotic HSA Results in Increased
Accumulation of Therapeutic Antibodies
We demonstrated the therapeutic applicability of this concept con-
jugating the clinically used mAb cetuximab (Erbitux) to Alexa680
and monitored its accumulation after preinjection (30 minutes) of
20% HSA or control vehicles. Time domain imaging and gating
for the fluorescent lifetime of tumoral cetuximab–Alexa680 fluores-
cence (Figure 5A) again demonstrated significantly increased uptake
of cetuximab in A431 tumors after 20% HSA treatment in compar-
ison to controls (Figure 5B).
Injection of Cetuximab after 20% HSA Infusion Delays
Tumor Growth After Stopping Cetuximab Treatment
Finally, to demonstrate the physiological effect on tumor growth, A431
tumor-bearing NMRI mice were treated with cetuximab (2 mg/ml)
30 minutes after injection of 20% HSA, 4% HSA, or 0.9% NaCl
(500 μl each) twice weekly. Control animals received only 0.9% NaCl
injections (500 μl) twice weekly. As expected, tumor growth in con-
trol mice was significantly augmented compared with cetuximab-treated
animals. Control animals were withdrawn from the experiment at
day 20 owing to large tumor volumes. No significant differences in
tumor growth were detected between all cetuximab-treated groups
until cetuximab application was stopped on day 30. Afterward, mice
treated with 20% HSA plus cetuximab continued tumor regression.
In contrast, a significant progression in A431 tumor growth was mea-
sured in all other treatment groups (Figure 6A). Furthermore, eval-
uation of blood pressure alterations after IV injection of 4% HSA,
20% HSA, or 0.9% NaCl in NMRI mice was performed through
intra-arterial blood pressure measurement for 3 hours. Although no
effect on blood pressure was observed in response to 4% HSA or
0.9% NaCl, treatment with 20% HSA caused a significant increase
in blood pressure just 1 hour after IV injection (Figure 6B), which
approached control levels after 3 hours. To prove the effectiveness of
cetuximab in reducing tumor cell growth, A431 cells were incubated
in vitro for 1 hour with different concentrations of cetuximab. Cells
were analyzed for phospho-p44/42 by Western blot analysis. It was
Figure 3. Tumor interstitial fluid pressure reduction through concentrated HSA and subsequent effects on the uptake of macromole-
cules. (A) Intravenous injection of 20% HSA significantly increased the plasma COP in Rowett nude rats. The COP rise correlated with a
significant lowering of TIFP after the injection of 20% HSA. (B) Uptake of Alexa488-coupled dextrans (10 kDa) in A431 tumors at distinct
time points after an IV injection of 20% HSA. (1) Untreated control tumor (no HSA injection), (2) dextran injection 1 hour after the HSA
injection, (3) dextran injection 2 hours after the HSA injection, and (4) dextran injection 3 hours after the HSA injection. Tissue slides were
prepared according to the description in Figure 2B.
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found that cetuximab diminishes phosphorylation of the proliferation-
associated mitogen-activated protein kinase p44/42 at concentra-
tion levels of 5 to 10 μg completely (Figure 6C ).
Discussion
An increased TIFP leads to a reduced convectional-driven transen-
dothelial fluid transport with clinical and therapeutic implications.
Particularly, the transport and uptake of therapeutic drugs [12] are
hampered, contributing to a lowered retention time of chemothera-
peutics within the tumor tissue [24,25]. In this respect, therapeutic
strategies enabling TIFP lowering may enhance the efficacy of anti-
tumor drugs [5]. It has been demonstrated that TIFP can be lowered
by local peritumoral application of prostaglandin E1 or hyaluronidase
[26,27]. Both treatment options feature the disadvantage that they are
limited solely to externally accessible tumors and cannot be applied in
a systemic treatment.
Here, we pursued a new approach to lower the TIFP, increase the
uptake of macromolecules into tumor tissue, and study the effect of
an increased COP on TIFP and the uptake of macromolecules. Ini-
tially, TIFP in A431 tumors of immunosuppressed mice and rats was
measured and related to tumor volume. In particular, A431 tumors
suggested a strong correlation between TIFP and tumor volume.
These results are in concert with published data showing that TIFP
increases with the tumor volume in other tumor species [28–30].
A431 tumors were punctured followed by IV injection of fluores-
cently labeled dextrans to check if lowering of TIFP increases the up-
take of macromolecular substances. As a result of tumor puncture, an
increased uptake of dextrans was detected in comparison to untreated
tumors or punctured control tissues (e.g., kidney). Nevertheless, the
use of the puncture method to lower TIFP is strictly limited to ex-
ternally accessible tumors and may not be transferred into the clinic.
Having demonstrated that reduced TIFP facilitates the uptake of
macromolecules, we investigated the effect of an increased COP on
the TIFP and consequent uptake of fluorescent-labeled macromole-
cules. We confirmed that IV injection of 20% HSA resulted in a sig-
nificant reduction of TIFP in immunosuppressed mice and rats.
Concurrently, the systemic blood pressure rose moderately for a short
period before dropping toward base levels. Furthermore, improved
delivery of IV administered fluorescently labeled dextrans or fluo-
rescently labeled cetuximab to tumors was achieved through the de-
crease of TIFP, with accumulation quantified by a novel time domain
molecular imaging.
The rationale for our new proposed therapy is that the high plasma
COP results in fluid mobilization from the tumor interstitium (as
well as other tissues) to the plasma. That this is actually occurring
is shown by the observed TIFP reduction and the concomitant in-
crease in blood pressure. Despite net bulk flow of fluid from tumor
Figure 4. Time domain fluorescence imaging of Alexa680-conjugated dextran accumulation 30 minutes after the IV injection of 20%
HSA. NOD/SCID mice bearing bilateral A431 tumors (>300 mm3) received an IV bolus injection of 500 μl of 20% HSA, 4% HSA, or 0.9%
NaCl (n = 6 per group). Thirty minutes later, the animals were IV injected with 50 μl of Alexa680-coupled dextrans. (A) Background and
raw fluorescence images were acquired before and after Alexa680-dextran injection. Raw fluorescence images of Alexa680-dextran
chromophor (first picture), with predominant circulation, and filtration through the kidneys, coupled with autofluorescence (as depicted
in the background scan, second picture), made it impossible to distinguish and quantify accumulated tumoral fluorescence. (B) Gating
for the fluorescence lifetime of tumor-accumulated Alexa680-dextran revealed specifically accumulated Alexa680-dextran in tumors (de-
picted in third picture of panel A). (C) Representatives of each group illustrated. (D) Average photon counts (±SEM) were plotted versus
time for Alexa680-dextran tumor-accumulated fluorescence, where *P < .05, **P < .01, ***P < .001. PC indicates photon counts.
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to plasma, macromolecules are transported in the opposite direction
as evidenced by the increased uptake. This apparent paradox may be
explained if we consider the sequence of effects evidenced by the en-
suing change in blood pressure and plasma COP and that the mac-
romolecule in question (i.e., macromolecular dextran or mAb, in the
present context called tracer) is transported by bulk flow as well as
diffusion. Furthermore, the well-known heterogeneity of tumor per-
fusion pattern and the tumor interstitium per se may also have an
influence. The initial rise in COP in plasma will mobilize tracer-free
interstitial fluid to plasma, again resulting in increased blood and
capillary pressure and filtration of tracer-containing fluid into the in-
terstitium. Such fluid mobilization occurs despite leaky vessels having
a high capillary permeability and a low osmotic reflection coefficient, σ,
in tumors (reviewed in [6,9]) and may be even higher in normal tissues,
such as muscle, having σ close to 1.0 [6]. In addition, the increased cap-
illary pressure and reduced IFP induced by the hyperoncotic solution
Figure 5. Time domain fluorescence imaging of Alexa680-conjugated cetuximab accumulation 30 minutes after the IV injection of 20%
HSA. (A) NOD/SCID mice bearing bilateral A431 tumors (n = 4; 300 mm3) were treated with cetuximab-Alexa680 (2 mg/ml) 30 minutes
after injection of 20% HSA, 4% HSA, or 0.9% NaCl (500 μl each), imaged by time domain fluorescence imaging (10-360 minutes) and
raw data gated for tumor-accumulated fluorescence lifetime of cetuximab-Alexa680 (1.5 nanoseconds). Representative images of each
group are depicted. (B) Graphical presentation of cetuximab-Alexa680 bound fluorescence (total photon counts ± SEM) versus time for
all tumors per treatment arm. *P < .05. PC indicates photon counts.
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will most likely result in perfusion of previously unperfused regions, thus
increasing the surface area available for diffusion. Accordingly, diffusion
as well as bulk flow works in the same direction and contributes to the
observed increased tracer uptake in the tumor.
If the proposed therapy were applied in a clinical situation, the
concurrent rise in systemic blood pressure may be a reason for con-
cern. We believe that such an effect would have been modest. Firstly,
the effect was moderate and temporary despite infusion of a strongly
hyperoncotic solution and the tendency to return to control levels at
180 minutes into the therapy. Furthermore, mobilization of fluid to
plasma and a rise in systemic blood pressure will result in a pressure
natriuresis and fluid excretion tending to normalize blood pressure in
individuals with normally functioning kidneys [31]. Clearly, this po-
tential problem has to be evaluated carefully in a clinical situation.
Although both test substances accumulate in the tumor after treat-
ment with 20% HSA, our data presume a different kinetic between
Figure 6. Increased COP facilitates the delivery of cetuximab and reduces tumor growth in vivo. (A) NMRI nude mice bearing bilateral
A431 tumors (n = 6 per treatment group; 300 mm3) were treated with cetuximab (2 mg/ml) 30 minutes after injection of 20% HSA,
4% HSA, or 0.9% NaCl (500 μl each) twice weekly. Control animals received only 0.9% NaCl injections (500 μl each) twice weekly.
Tumor growth was measured every 5 days. At day 30, cetuximab treatment was stopped at all treatment groups, and animals were
followed for tumor growth. Data are shown as mean ± SEM for n = 6 tumors per group. *P < .05 (20% HSA plus cetuximab vs all other
cetuximab groups), **P< .001 (control vs all other groups). (B) Arterial blood pressure was measured continuously from 0 minute before
and 180 minutes after the IV injection of 500 μl of 20% HSA, 4% HSA, or 0.9% NaCl. Data are shown as mean ± SEM for n = 4mice per
group. *P < .05. (C) In vitro incubation of A431 cells with cetuximab inhibits the phosphorylation of the proliferation-associated mitogen-
activated protein kinase p44/42-1/2 in a concentration-dependent manner.
820 Increased COP Facilitates Uptake of Macromolecules Hofmann et al. Neoplasia Vol. 11, No. 8, 2009
dextrans and cetuximab. Dextrans accumulate rapidly followed by a
gradual washout. In contrast, cetuximab accumulates slower, but the
retention time was markedly prolonged. It seems likely that dextrans,
because of their inert chemical character, do not bind to any structure
within the tumor and, therefore, show a fast clearance rate. Cetuximab
accumulates over time because of its high affinity toward the epidermal
growth factor receptor which is overexpressed on A431 tumor cells
[32]. In comparison to dextrans, the uptake of cetuximab into the tu-
mor interstitium is delayed because of its higher molecular weight
(151.8 vs 40 kDa for dextrans).
Experimental data suggest that antagonists against vascular endo-
thelial growth factor (e.g., bevacizumab) and platelet-derived growth
factor receptor (e.g., imatinib) also have some lowering effect on
TIFP [33,34]. It is assumed that bevacizumab, as a vascular endothe-
lial growth factor antibody, normalizes the tumor vasculature and,
therefore, lowers the TIFP. In the case of imatinib, the decreased TIFP
is attributed to a reduced contractility of fibroblasts residing in the tu-
mor extracellular matrix [34]. Although both substances given solely
only have marginal effects on tumor growth, a combination with clas-
sic chemotherapeutics such as 5-fluorouracil or dacarbazine has shown
some benefit [35,36]. It seems likely that this improvement is due to
the enhanced transvascular transport followed by the TIFP reduction
[37–40]. However, the TIFP-lowering effect does not appear immedi-
ately after substance application and implies a long-term remodeling of
the tumor physiology, for example, tumor vasculature or tumor extra-
cellular matrix [35,41,42]. Therefore, it is difficult to predict the maxi-
mum effect on TIFP reduction, which is optimal for the application of
chemotherapeutics.
The use of HSA, which interferes with the TIFP on a biophysical
level, enables a timely lowering of the TIFP and, therefore, allows es-
tablishment of distinct application protocols for antitumor drugs. In
conclusion, our data show for the first time that an increased plasma
COP lowers the TIFP. Moreover, it was shown that lowering of TIFP
enhances delivery and accumulation of macromolecules into solid tu-
mors and delays the tumor growth in the herein used animal model.
Thus, the present work proposes a strategic lowering of TIFP through
an increased plasma COP that may enhance the clinical efficacy of
antitumor therapies.
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